ATE506615T1 - Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten - Google Patents

Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten

Info

Publication number
ATE506615T1
ATE506615T1 AT00992018T AT00992018T ATE506615T1 AT E506615 T1 ATE506615 T1 AT E506615T1 AT 00992018 T AT00992018 T AT 00992018T AT 00992018 T AT00992018 T AT 00992018T AT E506615 T1 ATE506615 T1 AT E506615T1
Authority
AT
Austria
Prior art keywords
methods
reagents
diagnosis
imaging
treatment
Prior art date
Application number
AT00992018T
Other languages
English (en)
Inventor
Joseph Witztum
Sotirios Tsimikas
Wulf Palinski
Peter Shaw
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE506615T1 publication Critical patent/ATE506615T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
AT00992018T 1999-10-26 2000-10-26 Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten ATE506615T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16149399P 1999-10-26 1999-10-26
PCT/US2000/041651 WO2001032070A2 (en) 1999-10-26 2000-10-26 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease

Publications (1)

Publication Number Publication Date
ATE506615T1 true ATE506615T1 (de) 2011-05-15

Family

ID=22581404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00992018T ATE506615T1 (de) 1999-10-26 2000-10-26 Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten

Country Status (9)

Country Link
EP (1) EP1224461B1 (de)
JP (1) JP2003513027A (de)
AT (1) ATE506615T1 (de)
AU (1) AU773370B2 (de)
CA (1) CA2389849A1 (de)
DE (1) DE60045869D1 (de)
MX (1) MXPA02004244A (de)
NZ (1) NZ531712A (de)
WO (1) WO2001032070A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
IL161110A0 (en) 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
JP2003279571A (ja) * 2002-03-20 2003-10-02 Kyowa Hakko Kogyo Co Ltd 炎症性疾患検出方法、検出薬、およびその予防治療薬探索方法
AU2003267905B2 (en) * 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0202959D0 (sv) * 2002-10-04 2002-10-04 Forskarpatent I Syd Ab Ideon Peptide-Base passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
CN1968965B (zh) 2004-04-15 2015-12-16 阿瑟拉生物技术公司 磷酸胆碱偶联物和相应抗体
JP2008534508A (ja) * 2005-03-22 2008-08-28 メドスター ヘルス インコーポレイテッド 心血管疾患を診断および処置するための送達システムおよび方法
WO2011098407A1 (en) * 2010-02-12 2011-08-18 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Microspheres
EP2563816B1 (de) * 2010-04-27 2014-11-12 National Research Council of Canada Einzeldomänen-antikörper gegen icam 1 und verwendung davon
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
AU2011325946A1 (en) 2010-11-12 2013-05-30 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
EP2741770A4 (de) 2011-08-09 2014-12-31 Athera Biotechnologies Ab Antikörperbindung an phosphorylcholin (pc) und/oder pc-konjugate
AR087485A1 (es) 2011-08-09 2014-03-26 Athera Biotechnologies Ab Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1159497A (en) * 1996-11-08 1998-06-03 Regents Of The University Of California, The Methods and reagents for non-invasive imaging of atherosclerotic plaque
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
WO2001088547A2 (en) * 2000-05-12 2001-11-22 The Regents Of The University Of California Standardized oxidized ldl assay

Also Published As

Publication number Publication date
EP1224461A4 (de) 2003-06-25
MXPA02004244A (es) 2002-11-04
WO2001032070A3 (en) 2001-10-04
EP1224461A2 (de) 2002-07-24
CA2389849A1 (en) 2001-05-10
JP2003513027A (ja) 2003-04-08
WO2001032070A2 (en) 2001-05-10
NZ531712A (en) 2006-03-31
AU3790801A (en) 2001-05-14
EP1224461B1 (de) 2011-04-20
DE60045869D1 (de) 2011-06-01
AU773370B2 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
DE60045869D1 (de) Reagenzien und verfahren für diagnose, 'imaging' und behandlung von atherosklerotischen krankheiten
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
BRPI0619748B8 (pt) anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
ATE223051T1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
NO20050186D0 (no) Oligosakkaridbiomarkorer for mucopolysakkaridoser og andre beslektede forstyrrelser
ATE321570T1 (de) Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
Olsen et al. Indirect immunofluorescence microscopy of lichen planus
US20060257389A1 (en) Diagnosis of blood clots using fibrin-binding proteins bound with contrast agents
Sobreira et al. Prevalence of deep vein thrombosis and pulmonary embolism in superficial thrombophlebitis of the lower limbs: prospective study of 60 cases
DE50103907D1 (de) Verwendungen der Aldose-1-Epimerase (Mutarotase) für die Diagnose von Entzündungserkrankungen und Sepsis
EP2672266A3 (de) Verfahren zum Screening einer Lungen-Transplantation Kandidat für ein erhöhtes Risiko einer Abstoßung
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
ATE242484T1 (de) Verfahren zur untersuchung von nierenkrankheiten
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
RU2178711C1 (ru) Способ прогнозирования заболеваний копытец у коров после отела
Naredo et al. Doppler techniques
JP2008107275A (ja) アレルギー性皮膚炎の診断法
Eckrich et al. In vivo analysis of noise dependent activation of white blood cells and microvascular dysfunction in mice
WO2003039327A3 (en) Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
ATE360212T1 (de) Verfahren zur diagnose der effektivität der xenotypischen antikörpertherapie
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma
Tahir et al. Role of direct immunofluorescence on Tzanck smear and plucked hair in the diagnosis of pemphigus vulgaris
FR2828212B1 (fr) Methodes de diagnostic et de pronostic de la maladie de parkinson
RU2236010C1 (ru) Способ диагностики проходимости протоков слюнных желез

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties